| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
63 |
| Employees |
87 |
| Revenues (TTM) (Millions $) |
3 |
| Net Income (TTM) (Millions $) |
-90 |
| Cash Flow (TTM) (Millions $) |
2 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Chiasma Inc is a biopharmaceutical company.
It was founded in 2001 and is headquartered in Newton, Massachusetts, USA. Chiasma Inc is focused on developing and commercializing oral therapies that treat rare and serious diseases. Their core platform technology is called Transient Permeability Enhancer (TPE).
Chiasma has two main products in development, both utilizing their TPE technology. The first is a treatment for acromegaly, a condition caused by excess growth hormone in adults. The product is called Mycapssa and is an oral capsule that is designed to be taken twice daily. It was granted FDA approval in 2020.
The second product in development is a treatment for neuroendocrine tumors (NETs), which arise from hormone-producing cells in various parts of the body. The product is called octreotide capsules and is designed for patients who have difficulty swallowing the current standard of care, an injectable octreotide. The product has completed a Phase 3 clinical trial and is awaiting FDA approval.
Chiasma is also researching the potential of their TPE technology for other rare diseases, such as hypoparathyroidism.
In addition to their product pipeline, Chiasma has a strong intellectual property portfolio consisting of patents and pending applications. They have also secured funding to support their ongoing research and development efforts.
Overall, Chiasma Inc is a promising biopharmaceutical company that is developing innovative oral therapies for rare and serious diseases, utilizing their TPE platform technology.
Company Address: 140 Kendrick Street, Building C East Needham 2494 MA
Company Phone Number: 928-5300 Stock Exchange / Ticker: NASDAQ CHMA
|
%